Headlines about VIVUS (NASDAQ:VVUS) have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VIVUS earned a news impact score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.5633363716398 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern’s analysis:
- ETFs with exposure to VIVUS, Inc. : November 10, 2017 (finance.yahoo.com)
- Today Analysts Focus on: VIVUS, Inc., (NASDAQ: VVUS), ITT Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT (finance.yahoo.com)
- VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 (finance.yahoo.com)
- VIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPS (americanbankingnews.com)
VIVUS (NASDAQ VVUS) remained flat at $$0.64 during trading hours on Tuesday. 474,600 shares of the company were exchanged, compared to its average volume of 734,902. VIVUS has a 52 week low of $0.61 and a 52 week high of $1.47. The firm has a market cap of $67.80, a price-to-earnings ratio of 1.88 and a beta of 0.82. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.07. The firm had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.09) EPS. research analysts expect that VIVUS will post -0.32 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on VVUS shares. ValuEngine downgraded VIVUS from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research lowered VIVUS from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.